ArticleBreast cancer research and treatment2019
Breast cancer risk in relation to plasma metabolites among Hispanic and African American women.
Article in Breast cancer research and treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- Metabolic consequences of perioperative oral carbohydrates in breast cancer patients - an explorative study.BMC cancer · 2019Trial
- Elucidating the causal effects of plasma metabolites on breast cancer from multiple perspectives.International journal of surgery (London, England) · 2026Article
- Neighborhood deprivation, breast cancer outcomes and stress-related gene expression in leukocytes and tumor tissue.Breast cancer research : BCR · 2025Article
- Causal plasma metabolites for breast cancer risk: a two-sample Mendelian randomization study with colocalization evidence.Discover oncology · 2025Article
- Multiomic Analysis Links Neighborhood Disadvantage to Inflammatory Proteins and Tumorigenic Markers in ER+ Breast Cancer Plasma and Tumor Samples.Journal of proteome research · 2025Article
- Article
- Targeting estrogen mediated CYP4F2/CYP4F11-20-HETE metabolic disorder decelerates tumorigenesis in ER+ breast cancer.Biochemistry and biophysics reports · 2024Article
- The Role of Amino Acids in the Diagnosis, Risk Assessment, and Treatment of Breast Cancer: A Review.Current issues in molecular biology · 2023Review
- Identification of metabolic pathways contributing to ERScientific reports · 2023Article
- Article
- Association between human blood metabolome and the risk of breast cancer.Breast cancer research : BCR · 2023Article
- Anthropometric measures and breast cancer risk among Hispanic women in Puerto Rico.Cancer causes & control : CCC · 2022Article
- Neighborhood disadvantage and biological aging biomarkers among breast cancer patients.Scientific reports · 2022Article
- Circulating Carnitine Levels and Breast Cancer: A Matched Retrospective Case-Control Study.Frontiers in oncology · 2022Article
- Human Plasma Metabolomics for Biomarker Discovery: Targeting the Molecular Subtypes in Breast Cancer.Cancers · 2021Article
- Validation of plasma metabolites associated with breast cancer risk among Mexican Americans.Cancer epidemiology · 2020Article
- Toward a Standardized Strategy of Clinical Metabolomics for the Advancement of Precision Medicine.Metabolites · 2020Review
- Application of metabolomics in the diagnosis of breast cancer: a systematic review.Journal of Cancer · 2020Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
purposeThe metabolic etiology of breast cancer has been explored in the past several years using metabolomics. However, most of these studies only included non-Hispanic White individuals.
methodsTo fill this gap, we performed a two-step (discovery and validation) metabolomics profiling in plasma samples from 358 breast cancer patients and 138 healthy controls. All study subjects were either Hispanics or non-Hispanic African Americans.
resultsA panel of 14 identified metabolites significantly differed between breast cancer cases and healthy controls in both the discovery and validation sets. Most of these identified metabolites were lipids. In the pathway analysis, citrate cycle (TCA cycle), arginine and proline metabolism, and linoleic acid metabolism pathways were observed, and they significantly differed between breast cancer cases and healthy controls in both sets. From those 14 metabolites, we selected 9 non-correlated metabolites to generate a metabolic risk score. Increased metabolites risk score was associated with a 1.87- and 1.63-fold increased risk of breast cancer in the discovery and validation sets, respectively (Odds ratio (OR) 1.87, 95% Confidence interval (CI) 1.50, 2.32; OR 1.63, 95% CI 1.36, 1.95).
conclusionsIn summary, our study identified metabolic profiles and pathways that significantly differed between breast cancer cases and healthy controls in Hispanic or non-Hispanic African American women. The results from our study might provide new insights on the metabolic etiology of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.